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Abstract
Aims Pyruvate was shown to increase cardiac perfor-
mance in isolated human and animal myocardium and in
patients with chronic heart failure. We sought to investi-
gate the effects of pyruvate in acute heart failure.
Methods and results Patients presenting with cardiogenic
shock because of acute myocardial infarction were sub-
jected to standard care with primary PCI and intra-aortic
balloon pump (IABP). Then, a Swan–Ganz catheter was
placed in the pulmonary artery and hemodynamics was
analyzed before, during and after intracoronary adminis-
tration of 300 mmol/L pyruvate (360 ml/h). Pyruvate
induced a signiﬁcant increase in cardiac index (CI
2.23 ± 0.53 vs. 1.95 ± 0.45 L min
-1 m
-2; p\0.05),
stroke volume index (SVI, 29 ± 6 vs. 26 ± 5m Lm
-2;
p\0.05), and mean systemic arterial pressure (mean SAP,
95 ± 9 vs. 87 ± 9 mmHg; p\0.05), whereas heart rate
did not signiﬁcantly change. The effects occurred rapidly
within 30 min and were reversible within 10 min.
Conclusion Intracoronary pyruvate might show beneﬁcial
effects in severe acute heart failure in addition to treatment
with catecholamines and IABP. These effects should be
further investigated in randomized controlled trials.
Keywords CARDIAC output  Inotropic agents 
Metabolism  Heart failure  Shock
Abbreviations




IABP Intra-aortic balloon pump
PAP Pulmonary artery pressure
PCI Percutaneous coronary intervention
PCWP Pulmonary capillary wedge pressure
PVR Pulmonary vascular resistance
RAP Right atrial pressure
SAP Systemic arterial pressure
STEMI ST-segment elevation myocardial infarction
SVI Stroke volume index
SVR Systemic vascular resistance
Introduction
Cardiogenic shock following myocardial infarction has a
poor prognosis with mortality between 40 and 60% [6].
Prognosis improves with PCI. However, in many cases
despite maximum therapy including inotropic agents and
IABP cardiac output and blood pressure are not adequate to
prevent progressive organ failure. Therefore, new strategies
to rapidly improve hemodynamics after PCI are urgently
needed.
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DOI 10.1007/s00392-010-0261-4It has been suggested recently that pyruvate which is a
key intermediate in the glycolytic and pyruvate dehydro-
genase pathways shows beneﬁcial hemodynamic effects.
The use of different animal species showed that pyruvate
exerted positive inotropic effects in vitro [19] and in vivo
[12, 13, 15, 23]. Similar results were found in isolated
multicellular preparations from end-stage failing human
hearts [7]. Measuring oxygen consumption by the diffusion-
microelectrode technique in isolated contracting rabbit
myocardium, it could be demonstrated that economy of
myocardial contraction remained unchanged with pyruvate
despite a substantial increase in force–time integral whereas
b-adrenergic stimulation decreased economy [11]. More-
over, pyruvate potentiated the inotropic response of
b-adrenergic stimulation in isolated animal [21] and human
myocardium [10]. Previous in vivo studies in patients with
chronic compensated heart failure have demonstrated
increased CO, improved relaxation and decreased left ven-
tricular ﬁlling pressure and HR with intracoronary pyruvate
infusion [8, 9].
Thus, pyruvate may have beneﬁcial effects in acute
severe heart failure and cardiogenic shock, but no data is
currently available directly supporting this hypothesis.
We therefore investigated the effects of intracoronary
pyruvate infusion in patients with severe circulatory failure
due to acute coronary syndrome necessitating pharmaco-
logical and mechanical support.
Methods
Patients
Patients were eligible for participation if they were pre-
senting with cardiogenic shock because of acute myocar-
dial infarction and if primary PCI could be successfully
performed. Cardiogenic shock was deﬁned according to
current guidelines [2]. Detailed inclusion and exclusion
criteria are given in Table 1. Written informed consent was
obtained from patients or close relatives in unconscious
patients prior to the study. Alternatively, the study was
performed with regard to the patients’ presumed will.
In the latter ones, written consent was obtained as soon as
possible after study termination from patients after having
regained consciousness or from close relatives. One patient
with presumed anterior wall STEMI at the initial evalua-
tion was excluded from further analyses because continu-
ative evaluation revealed chronic anterior wall aneurysm
by echocardiography, absence of rise in troponin t, failure
of ST segment resolution after successful PCI, and signif-
icant decompensated aortic stenosis as the cause of acute
cardiac failure. Eight patients were included in the ﬁnal
analyses: one was female and seven were male. The
median age was 68 years (range 40–84). All patients were
on treatment with catecholamines (epinephrine 0.03–0.34
lgk gm i n
-1, n = 6; norepinephrine 0.03–0.63 lgk gm i n
-1,
n = 5). HR was 89 ± 18 min
-1 and systolic pressure was
92 ± 8 mmHg (mean ± 95% CI). The study was reviewed
and approved by the ethical committee of the University
Medical Center of Goettingen.
Cardiac catheterization and treatment of myocardial
infarction
Cardiac catheterization, PCI and placement of an IABP
were performed according to current guidelines [1, 2, 22].
After termination of PCI the guiding catheter was left in the
ostium of the coronary artery. During these interventions
all measures were undertaken to obtain stable conditions
prior to the study protocol: Catecholamine doses and
ventilation conditions were adjusted to obtain sufﬁcient
hemodynamics and blood gases. Sedatives and muscle
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age, 18–85 years Failure of PCI or need for CABG
Weight, 45–110 kg Cardiogenic shock of other origin than ischemic
(e.g., tamponade, valvular disease, arrhythmogenic)
Height, 150–195 cm Instability necessitating signiﬁcant change of conditions
(e.g., catecholamine dose, ventilation) before pyruvate infusion
Acute myocardial infarction Failure to insert intra-aortic balloon pump
Successful primary PCI Malignant tumor
Cardiogenic shock Pregnancy or lactation
Need for catecholamines or intra-aortic
balloon pump
Poor compliance
Stable conditions in hemodynamics, rhythm
and ventilation before pyruvate infusion
Alcohol or drug abuse
Participation in concurrent clinical trial
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123relaxants were administered as needed. Bicarbonate was
administered to counterbalance acidosis if present. Coma-
tose survivors of cardiac arrest were cooled to 32–34Cb y
infusion of cold NaCl 0.9% solution for reasons of neu-
roprotection. 150–300 mg of amiodarone was injected if
relevant arrhythmias were present. After these measures,
all conditions were kept stable.
Measurements of intracoronary pyruvate effects
A 7F Swan–Ganz catheter was placed in the pulmonary
artery from a femoral vein. About 30–45 min after having
performed all interventions and having gained stable con-
ditions; CI was determined in triplicate by the thermodi-
lution technique and PCWP was measured. After a waiting
period of 30 min in order to assure stable conditions,
intracoronary NaCl 0.9% was administered via the guiding
catheter with an infusion rate of 360 mL/h. After 10 min,
HR, SAP, RAP, PAP, PCWP, SVI and CI were determined.
After these measurements, intracoronary NaCl 0.9% infu-
sion was stopped and intracoronary pyruvate 300 mmol/L
was administered at an identical infusion rate of 360 mL/h
for 30 min. Every 10 min, hemodynamic measurements
were repeated. Then, pyruvate was stopped and intracoro-
nary NaCl 0.9% (360 mL/h) was given for another 10 min
followed by ﬁnal hemodynamic measurements. After ter-
mination of measurements, patients were transferred to the
intensive care unit, immediately, and subjected to standard
treatment.
Statistical analyses
GraphPad Prizm Version 5 was used for statistical analyses.
Previous studies in stable patients with chronic heart failure
showed statistically signiﬁcant effects of intracoronary
pyruvate in small numbers of patients (8, 9). Because of the
expected difﬁculties in patient recruitment, the study pro-
tocol allowed analyses of data after eight patients and ter-
mination of the study if statistically signiﬁcant differences
were present. Data are expressed as mean ± 95% conﬁ-
dence interval. Differences between means were tested for
statisticalsigniﬁcanceby1-wayrepeatedmeasuresANOVA
followed by Newman–Keuls multiple comparison tests.
A p value of\0.05 was accepted as statistically signiﬁcant.
Results
A summary of hemodynamic measurements and pyruvate
effects is given in Table 2. Cardiac performance was
severely impaired in all patients. Baseline hemodynamics
directly before pyruvate were as follows: CI 2.07 ± 0.47,
HR 76 ± 8, SVI 27 ± 5, mean SAP 93 ± 7, mean
PCWP 23 ± 6. Continuous intracoronary pyruvate infu-
sion induced an increase in CI that amounted to 2.23 ±
0.53 L min
-1 m
-2 after 30 min. After intracoronary
pyruvate was stopped, CI rapidly dropped down to 1.95 ±
0.45 L min
-1 m
-2 within 10 min (p\0.05, Fig. 1). Sim-
ilarly, there was a rise in SVI to 29 ± 6m Lm
-2 after
30 min pyruvate. After pyruvate was stopped SVI declined
to 26 ± 5m Lm
-2 within 10 min (p\0.05, Fig. 1). Mean
SAP was 95 ± 9 mmHg after 30 min of intracoronary
pyruvate infusion and decreased to 87 ± 9 mmHg 10 min
after pyruvate was stopped (Fig. 1). Even though these
effects were not pronounced, an increase in CI, SVI, and
mean SAP was clearly found in most patients and differ-
ences as a result of the intervention were statistically sig-
niﬁcant (Fig. 1). By comparing hemodynamics after
30 min of pyruvate infusion (point in time 40 min) to
values 10 min after cessation (point in time 50 min), we
calculated a net positive pyruvate effect of 15 ± 5% on CI,
of 16 ± 5% on SVI, and of 10 ± 8% on mean SAP in
addition to catecholamine treatment and mechanical sup-
port by IABP. CI, SVI, and mean SAP tended to drop after
termination of pyruvate infusion as compared to baseline
values; however, neither of these changes was statistically
signiﬁcant. In parallel to changes in CI, SVI, and mean
SAP, there was a tendency for a drop in SVR and PVR
under the inﬂuence of pyruvate. Yet, these changes were
not statistically signiﬁcant as well. Pyruvate did not induce
signiﬁcant changes in HR, mean PCWP, mean RAP,
and mean PAP (Table 2).
Discussion
The present study shows that intracoronary pyruvate has
positive inotropic effects in patients with cardiogenic
shock despite medical treatment with catecholamines and
Table 2 Hemodynamic effects of intracoronary pyruvate in addition








-1)7 6 ± 97 6 ± 7
CI (L min
-1 m
-2) 2.23 ± 0.53 1.95 ± 0.45*
SVI (mL m
-2)2 9 ± 62 6 ± 5*
Mean SAP (mmHg) 95 ± 98 7 ± 9
Mean PAP (mmHg) 33 ± 63 1 ± 4
Mean PCWP (mmHg) 23 ± 72 2 ± 4
Mean RAP (mmHg) 16 ± 31 6 ± 3
SVR (dyn s cm
-5) 1,608 ± 354 1,635 ± 325
PVR (dyn s cm
-5) 216 ± 136 236 ± 159
* Means p\0.05
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123mechanical support by IABP. We found an increase in CI
and SVI by 15 ± 5 and 16 ± 5%, respectively, as an effect
of pyruvate that was not secondary to increases in HR.
Moreover, mean SAP was increased by 10 ± 8%. All other
conditions were kept stable during pyruvate infusion and
no signiﬁcant differences of any hemodynamic parameter
were detected between values at baseline and after com-
plete reversal of pyruvate effects. Thus, these effects can-
not be attributed to standard interventions related to
treatment of myocardial infarction and cardiogenic shock
or to changes in hemodynamics other than that caused by
intracoronary pyruvate.
In a previous study, we could show that the observed
beneﬁcial effects of pyruvate on hemodynamics mainly
resulted from direct myocardial effects and not from
altered loading conditions because intracoronary pyruvate
was almost completely extracted from the coronary circu-
lation by the myocardium and did not induce systemic
vasodilatation [9]. Furthermore, it was shown that pyruvate
does not induce coronary vasodilatation [4]. The underly-
ing mechanisms of pyruvate on the myocardium have been
extensively investigated in animal and human myocardium
[4, 7, 10, 12–15, 19, 21, 23]. It was demonstrated that
pyruvate increases the energetic stimulation of the sarco-
plasmic reticulum calcium pump due to an increase in
phosphorylation potential with enhanced free energy of
ATP hydrolysis [4, 19]. This promotes relaxation of the
myoﬁlaments and also results in enhanced calcium content
of the sarcoplasmic reticulum, which in turn results in more
calcium available for systolic release and activation of
contractile proteins [5, 7]. In addition, it was shown that
pyruvate increases intracellular pH which may partly result
from uptake of pyruvate and protons into the mitochondria
by the monocarboxylate–proton symporter [7, 17]. The
increase in intracellular pH leads to an enhanced calcium
sensitivity of contractile proteins and force development
[3].
These effects on the cellular and molecular level had
been previously shown to translate into pronounced bene-
ﬁcial effects on systolic and diastolic cardiac performance
in patients with chronic heart failure. In a previous study
in patients with chronic stable heart failure, pyruvate
NaCl 0.9% Pyruvat 300 mmol/L NaCl 0.9% NaCl 0.9% Pyruvat 300 mmol/L NaCl 0.9%
A B Cardiac Index Stroke Volume Index
*
NaCl 0.9% Pyruvat 300 mmol/L NaCl 0.9%
C Mean Systemic Arterial Pressure
Fig. 1 Graphs showing changes in CI (a), SVI (b), and mean SAP
(c) under the inﬂuence of NaCl 0.9% and pyruvate 300 mmol/L at
different points in time. Interventions are indicated by arrows. There
was a signiﬁcant effect of pyruvate on each hemodynamic parameter
as calculated by repeated measures ANOVA. *Means p\0.05 versus
50 min. Neither of all parameters showed signiﬁcant differences at
50 min as compared to 10 min indicating stable hemodynamics at
baseline
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123increased cardiac index without increasing HR [8, 9].
These ﬁndings resulted from an increase in left ventricular
ejection fraction [8]. Moreover, positive effects on maxi-
mum rate of left ventricular isovolumic pressure rise were
found by use of a micromanometer catheter [8]. Interest-
ingly, in the present study pyruvate exhibited beneﬁcial
effects on systolic cardiac performance in acute heart
failure ancillary to IABP. IABP was suggested to increase
left ventricular ejection fraction and CO [16]. With regard
to diastolic function, the previous studies in chronic heart
failure demonstrated that pyruvate decreased PCWP [9]
and left ventricular end-diastolic pressure [8]. Contrasting
these ﬁndings, the effects of pyruvate on left ventricular
ﬁlling pressure as measured by PCWP were absent in the
present study. This lack of an unloading effect of pyruvate
might be secondary to the action of IABP which induces a
pronounced systolic unloading of the heart [16] implying
that potential effects of pyruvate on left ventricular preload
might be masked by IABP. It is of note that the role of
IABP in acute ischemic shock was recently questioned
[18, 20]. The present study was designed and conducted in
consideration of current guidelines that strongly recom-
mend IABP in acute myocardial infarction complicated by
shock [1, 22]. However, the evidence supporting this rec-
ommendation is rather limited. Thus, investigation of the
effects of intracoronary pyruvate in acute heart failure
without IABP might be mandatory.
After termination of pyruvate, CI, SVI, and mean SAP
tended to drop below the baseline values. These changes
were not statistically signiﬁcant. However, examination of
this phenomenon in further studies might be worthwhile in
order to prevent a worse outcome due to sudden termina-
tion of therapy. The major shortcoming of pyruvate is the
necessity of intracoronary application. Because it is rapidly
metabolized and the hemodynamic effect requires doses
above 1 mM very high doses would be necessary if it was
administered intravenously. Such high doses, however,
would lead to sodium overload and hyperosmolarity if the
sodium salt of pyruvic acid was used as in the present
study. However, in specialized centers with invasive
facilities the intracoronary route might be an option for
patients with cardiogenic shock refractory to standard care.
Moreover, these problems may be overcome by the
development of novel formulations such as the choline salt.
In summary, pyruvate might have the potential of a
favorable agent in acute heart failure and might serve as an
adjunctive therapy to catecholamines. It might save cate-
cholamines that are potentially harmful. Moreover, the
effects of pyruvate might especially help in acute ischemic
heart failure because the inotropic effects of pyruvate
occurred without worsening of myocardial economy. These
potentially beneﬁcial effects of pyruvate should be inves-
tigated in randomized controlled trials.
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